GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,308.00
-10.00 (-0.76%)
At close: 5:04PM GMT
Stock chart is not supported by your current browser
Previous close1,318.00
Open1,313.00
Bid0.00 x 175400
Ask0.00 x 417900
Day's range1,300.00 - 1,317.83
52-week range1,300.00 - 1,724.50
Volume6,442,515
Avg. volume9,156,933
Market cap63.51B
Beta1.15
PE ratio (TTM)33.45
EPS (TTM)39.10
Earnings date5 Feb 2018 - 9 Feb 2018
Forward dividend & yield1.01 (5.14%)
Ex-dividend date2017-08-10
1y target est1,571.96
  • Why GlaxoSmithKline plc is my FTSE 100 stock pick for the next decade
    Fool.co.uk23 hours ago

    Why GlaxoSmithKline plc is my FTSE 100 stock pick for the next decade

    The FTSE 100 (INDEXFTSE:UKX) is still probably the best index for long-term investors, and GlaxoSmithKline plc (LON: GSK) could be its hottest prospect right now.

  • Theravance Shares Rise on Approval of Glaxo's COPD Therapy
    Zacks2 days ago

    Theravance Shares Rise on Approval of Glaxo's COPD Therapy

    Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

  • Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
    Zacks2 days ago

    Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

    Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

  • Reuters - UK Focus3 days ago

    Endo unit cleared of liability in first testosterone replacement trial

    A federal jury in Chicago said on Thursday that Endo International (NasdaqGS: ENDP - news) 's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks. Matthew Maletta, Endo's chief legal officer, said in a statement that Testim was safe and Endo would continue to vigorously defend against similar claims.

  • Reuters - UK Focus4 days ago

    AstraZeneca ticks another box as U.S. approves severe asthma drug

    AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares (Berlin: DI6.BE - news) in AstraZeneca were 1 percent higher on Wednesday following the overnight news.

  • Reuters4 days ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's (GSK.L) new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S). The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.

  • Reuters - UK Focus4 days ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. ...

  • Business Wire4 days ago

    Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

  • The Wall Street Journal4 days ago

    [$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases

    The Crown Prince of Abu Dhabi launched a fund with the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis, which leads to a condition known as elephantiasis.

  • Reuters - UK Focus4 days ago

    BUZZ-VBI Vaccines shoots up on BMO "outperform" initiation

    ** Shares of biotech firm VBI Vaccines Inc. jumped more than 8 pct on Weds after BMO initiated coverage at "outperform" ** Broker sets $11 PT, about 150 pct above current price ** Lead analyst ...

  • Reuters5 days ago

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (BAYGn.DE) has hired the head of Nestle's (NESN.S) baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon (AMZN.O) and other online platforms. Bayer has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday. Bayer was caught off guard by the speed of U.S. consumers switching to online stores at the expense of established drugstores.

  • Reuters - UK Focus5 days ago

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (Swiss: BAYN-EUR.SW - news) has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online platforms. Bayer (IOB: 0P6S.IL - news) has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday.

  • Reuters - UK Focus5 days ago

    AstraZeneca ticks another box as U.S. approves severe asthma drug

    AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares (Berlin: DI6.BE - news) in AstraZeneca were 1 percent higher on Wednesday following the overnight news.

  • Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
    Zacks6 days ago

    Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

    GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.

  • Interview: Bill Gates makes $100 million personal investment to fight Alzheimer's
    Reuters7 days ago

    Interview: Bill Gates makes $100 million personal investment to fight Alzheimer's

    Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease. The investment - a personal one and not part of Gates' philanthropic Bill & Melinda Gates Foundation - will be followed by another $50 million in start-up ventures working in Alzheimer's research, Gates said. With rapidly rising numbers of people suffering from Alzheimer's and other forms of dementia, the disease is taking a growing emotional and financial toll as people live longer, Gates told Reuters in an interview.

  • It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
    Motley Fool9 days ago

    It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval

    Sure, Dynavax has already chalked up huge gains. But there's still room for the biotech stock to go higher.

  • Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
    Zacks10 days ago

    Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

    Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

  • AstraZeneca's Dividend Commitment Comes at a Cost
    Bloomberg11 days ago

    AstraZeneca's Dividend Commitment Comes at a Cost

    Cash is already tight, and about to get much tighter.

  • Reuters - UK Focus11 days ago

    More women on UK boards but top jobs out of reach - report

    More women are sitting on the boards of Britain's largest 100 companies, with big gains in the traditional male bastions of building and manufacturing, yet very few hold the top jobs, a report said on Thursday. Women hold 28 percent of directors' seats on the boards of FTSE 100 companies, against 11 percent a decade ago, putting Britain on track to meet a target of one in three by 2020, said the Cranfield School of Management and Exeter University. "Companies are simply looking to get women into board seats to hit short-term diversity targets rather than creating cultures where the best people get the job irrespective of gender," said Griselda Togobo of business group Forward Ladies.

  • Reuters11 days ago

    AstraZeneca rides China wave as rival GlaxoSmithKline struggles

    AstraZeneca (AZN.L) is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline (GSK.L). China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies. "We are in a special place in China," Chief Executive Pascal Soriot said on Thursday, after presenting financial results.

  • Reuters - UK Focus11 days ago

    AstraZeneca rides China wave as rival GlaxoSmithKline struggles

    AstraZeneca (NYSE: AZN - news) is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline (Other OTC: GLAXF - news) . China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies. "We are in a special place in China," Chief Executive Pascal Soriot said on Thursday, after presenting financial results.

  • Reuters - UK Focus11 days ago

    Thousands of drugs face Brexit risk, makers to duplicate testing

    Supplies of thousands of medicines are at risk of disruption if Britain leaves the European Union without a trade deal, forcing manufacturers to prepare for duplicate product testing to ensure their drugs stay on the market. More than 2,600 drugs have some stage of manufacture in Britain and 45 million patient packs are supplied from the UK to other European countries each month, while another 37 million flow in the opposite direction, drugmakers said on Thursday. Brexit threatens the free flow of these goods, given stringent medicine regulations that will require the retesting of drugs shipped across borders in the absence of an agreed trading arrangement.

  • Reuters - UK Focus11 days ago

    Britain's FTSE under pressure as Burberry revamps its strategy

    A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus. Britain's blue-chip FTSE 100 index was flat in percentage ...

  • Reuters11 days ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    The dispute between the Jordan-based firm, its partner Vectura (VEC.L) and the U.S FDA delays any eventual approval of the generic version of the drug. Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters - UK Focus11 days ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes